Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Glecaprevir/Pibrentasvir Efficacy & Safety Assessed

J Hepatol; ePub 2018 Nov 23; D’Ambrosio, et al

In a large cohort of patients with chronic hepatitis C virus (HCV) infection, glecaprevir/pibrentasvir (G/P) administered for 8 or 12-16 weeks was found to be both effective and safe, a new study found. All HCV patients consecutively starting G/P between October 2017 and January 2018 within the NAVIGATORE-Lombardia Network were analyzed. Researchers found:

  • 723 patients (median age 58 years, body mass index [BMI] 23.9 kg/m2; 50% male) were treated with G/P; 89% for 8 weeks.
  • G/P combination demonstrated excellent sustained virological response (SVR) rates (99.2%).
  • Male gender and non-HCV-3 genotype were associated with the lowest rates of SVR in patients treated for 8 weeks.
  • No major safety issues were reported; mild adverse events were reported in 8.3% of patients.


D’Ambrosio R, Pasulo L, Puoti M, et al. Real-life effectiveness and safety of Glecaprevir/Pibrentasvir in 723 patients with chronic hepatitis C. [Published online ahead of print November 23, 2018]. J Hepatol. doi:10.1016/j.jhep.2018.11.011.